Diametric Capital’s Allogene Therapeutics ALLO Stock Holding History

Diametric Capital’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-85,343	Closed	-$922K	–	305
2022 Q3	$922K	Buy	+85,343	New	+$1.16M	0.46%	70

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Diametric Capital's ALLO Position: Q4 2022 in Review

Diametric Capital sold out of Allogene Therapeutics (ALLO) in Q4 2022, closing a stake of 85,343 shares — an estimated $922K sold.

Diametric Capital first reported a position in ALLO in Q3 2022 and held it in 1 quarter. The position peaked at $922K in Q3 2022. 168 funds tracked by Wall St. Rank hold ALLO as of Q4 2022.

Diametric Capital reported no remaining Allogene Therapeutics position as of Q4 2022 after selling out during the quarter.
Diametric Capital sold 85,343 Allogene Therapeutics shares in Q4 2022, an estimated $922K.
Diametric Capital first reported a position in Allogene Therapeutics in Q3 2022 and held it in 1 quarter.
Diametric Capital's Allogene Therapeutics position peaked at $922K in Q3 2022.
168 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2022.

Based on Diametric Capital's 13F filing for Q4 2022, filed 29 Mar 2023.